Skip to main content
SpringerLink
Log in

Treatment of vertigo depends on accurate diagnoses of vertigo type

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table 1
Table 2
Table 3

References

  1. Hain TC, Uddin M. Pharmacological treatment of vertigo. CNS Drugs 2003; 17 (2): 85–100.

    Article  PubMed  CAS  Google Scholar 

  2. British National Formulary No. 46. London: The Pharmaceutical Press, 2003 Sep

  3. Drug Information. USA: American Society of Health-System Pharmacists, 2003

  4. de Waele C, Muhlethaler M, Vidal PP. Neurochemistry of the central vestibular pathways. Brain Res Brain Res Rev 1995; 20 (1): 24–46.

    Article  PubMed  Google Scholar 

  5. Pyykko I, Schalen L, Jantti V. Transdermally administered scopolamine vs. dimenhydrinate. I: effect on nausea and vertigo in experimentally induced motion sickness. Acta Otolaryngol 1985; 99 (5–6): 588–96.

    Article  PubMed  CAS  Google Scholar 

  6. Takeda N, Morita M, Hasegawa S, et al. Neurochemical mechanisms of motion sickness. Am J Otolaryngol 1989; 10 (5): 351–9.

    Article  PubMed  CAS  Google Scholar 

  7. Padoan S, Korttila K, Magnusson M, et al. Reduction of gain and time constant of vestibulo-ocular reflex in man induced by diazepam and thiopental. J Vestib Res 1990; 1 (1): 97–104.

    PubMed  Google Scholar 

  8. Lee JA, Watson LA, Boothby G. Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 1986; 57 (1): 45–8.

    PubMed  CAS  Google Scholar 

  9. Aoki M, Ito Y, Miyata H. Prevention of vestibular deafferentation-induced spontaneous nystagmus with pretreatment of Ca2+ channel/N-methyl-D-aspartic acid receptor antagonists in guinea pigs. Acta Otolaryngol 1998; 118 (4): 554–6.

    Article  PubMed  CAS  Google Scholar 

  10. Rascol O, Clanet M, Montastruc JL. Calcium antagonists and the vestibular system: a critical review of flunarizine as an antivertigo drug. Fundam Clin Pharmacol 1989; 3: 79s–87s

    Article  PubMed  Google Scholar 

  11. Macleod AD. Ondansetron in multiple sclerosis. J Pain Symptom Manage 2000; 20 (5): 388–91.

    Article  PubMed  CAS  Google Scholar 

  12. Brandt T. Benign paroxysmal positioning vertigo. Adv Otorhinolaryngol 1999; 55: 169–94

    PubMed  CAS  Google Scholar 

  13. James AL, Burton MJ. Betahistine for Meniere’s disease or syndrome [CD001873]. The Cochrane Database Systematic Reviews. Available in the Cochrane Library [database on disk and CD ROM]. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2001

    Google Scholar 

  14. Rice GP, Ebers GC. Ondansetron for intractable vertigo complicating acute brainstem disorders. Lancet 1995; 345 (8958): 1182–3.

    Article  PubMed  CAS  Google Scholar 

  15. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999; 20 (3): 277–87.

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Treatment of vertigo depends on accurate diagnoses of vertigo type. Drugs Ther. Perspect 19, 16–20 (2003). https://doi.org/10.2165/00042310-200319120-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319120-00006

Keywords

Search

Navigation